Gritstone bio, Inc.
GRTS · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.28 | 0.53 | -0.20 |
| FCF Yield | -32.30% | -12.12% | -17.36% | -16.22% |
| EV / EBITDA | -6.51 | -9.05 | -8.62 | -7.45 |
| Quality | ||||
| ROIC | -21.40% | -36.60% | -25.66% | -21.95% |
| Gross Margin | -2,707.02% | -3,455.10% | -6,524.14% | -25.50% |
| Cash Conversion Ratio | 1.15 | 0.83 | 1.12 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.41% | -44.22% | -62.14% | -56.41% |
| Free Cash Flow Growth | 20.37% | 2.48% | -7.41% | 1.54% |
| Safety | ||||
| Net Debt / EBITDA | -2.46 | -1.60 | -1.43 | -1.85 |
| Interest Coverage | -21.82 | -32.02 | -33.52 | -38.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.34 |
| Cash Conversion Cycle | 75.47 | 3.90 | 537.97 | 85.64 |